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Abstract
Background: The preparation of HTA reports requires a great deal of time, effort and resource, and there is a desire to 
improve efficiency, avoid duplication of effort and facilitate the transfer of knowledge between countries. This is of 
particular importance for countries with more limited resources which have less capacity to produce their own reports. 
The aim of this study was to investigate the extent of duplication of published Health Technology Assessment (HTA) 
reports, on the same technology, for the same indication; using positron emission tomography (PET) for lung cancer 
and Hodgkin's disease as a case study. This was done in order to assess the potential usefulness of a toolkit developed 
to aid in the adaptation of HTA reports from one context or country to another.
Methods: A systematic search of the National Institute for Health Research (NIHR) CRD HTA database was conducted in 
June 2008 in order to identify full HTA reports containing information on the use of PET for lung cancer and Hodgkin's 
disease, written in English, and readily available on the web. The contents of the reports identified were then examined 
to assess the extent of duplication of content between reports and potential for the use of the toolkit.
Results: From 132 records of HTA reports about PET, 8 reports were identified as fulfilling all the criteria set, and 
therefore demonstrating potential duplication of effort. All these reports covered four similar domains, technology use, 
safety, effectiveness and economic evaluation. Five of the reports also considered organisational aspects.
Conclusions: There was some duplication of effort in the preparation of HTA reports concerned with the use of PET for 
lung cancer and Hodgkin's disease. This is an example of where resource could have been conserved and time saved 
by the use of a toolkit developed to aid in the adaptation of HTA reports from one context to another.
Background
The preparation of HTA reports requires a great deal of
time, effort and resource. There is a desire to improve
efficiency, avoid duplication of effort [1-3] and facilitate
the sharing of information between countries. This con-
servation of resource could be maximised by a process of
adaptation, utilising the relevant parts of other HTA
reports prepared for use in other countries or contexts
[4]. The stage of development and amount of resource
available to HTA institutions within member states of the
European Union varies considerably; and varies even
more worldwide. This process of adaptation could be of
particular importance for less well resourced agencies e.g.
outside the EU, and when several agencies require infor-
mation on the same technology at a similar stage of tech-
nological development.
The European Network for Health Technology Assess-
ment (EUnetHTA) [5] was established to strengthen links
between HTA agencies in Europe and to develop tools to
aid in HTA development [6,7]. This project consisted of
e i g h t  s e p a r a t e l y  m a n a g e d  w o r k  p a c k a g e s  ( W P 1 - 8 ) .
Resources such as the International Network of Agencies
for Health Technology Assessment (INAHTA) checklist
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[8] and the Equity-Oriented Toolkit for Health Technol-
ogy [9] are available to guide those using and preparing
HTA reports, however information contained in reports
can rarely be used in different contexts without being
extracted, updated and adapted [4]. Previous publications
have described the development of a toolkit [4,10] and
accompanying glossary [11] which were developed to aid
the process of adaptation of HTA reports[10,12], as part
of the output from work package 5 of the EUnetHTA
project 2006-8 [13].
This toolkit is composed of a series of checklists and
resources which identify or clarify the relevance, reliabil-
ity and transferability of data and information from exist-
ing reports. It comprises two sections: (i) speedy sifting; a
screening tool which would enable 'speedy sifting' of
existing HTA reports to assess the relevance of the HTA
report for adaptation, and (ii) main toolkit; a more com-
prehensive tool with questions on reliability and issues
regarding transferability. The toolkit can be used to adapt
a whole HTA report or parts of it.
The toolkit provides checklists and resources for five
HT A report areas of interest which we have termed as
domains: technology use and development, safety, effi-
cacy and effectiveness, cost-effectiveness and organisa-
tional aspects. The extent to which adaptation is possible
depends on the generalisability of the topic under consid-
eration and the different contexts for which the informa-
tion is required [14-16]. Some domains within these
reports are more readily adapted to other contexts. Effec-
tiveness, safety, and technology use are examples of
domains which may readily lend themselves to the pro-
cess; specific issues relating to cultural, legal or political
aspects may not be so appropriate for adaptation [4,10].
The toolkit has been subjected to a process of quality
assurance testing [4], (HTA partner organisations have
tested the toolkit using it to aid in the adaptation of
selected reports to meet the needs of their own health
services) and has been found useful.
Positron Emission Tomography (PET) is a 3D imaging
technique of wide application, which measures physio-
logical function by looking at blood flow, metabolism,
neurotransmitters, and radio-labelled drugs [17]. PET is a
complex technology; it can operate in several modalities
e.g. full ring PET, partial ring PET, and gamma camera
PET.
A number of agencies have produced HTA reports on
use of the technique for a variety of indications. PET was
chosen as a suitable topic for this case study because of
this large number of reports and because of the earlier
debate concerning reliability of HTA reports concerning
PET [18,19]. One clinical use of PET is in the field of
oncology to distinguish between benign and malignant
tumours. To date some of the strongest evidence of effec-
tiveness and cost effectiveness of the techniques is
emerging in relation to lung cancer and Hodgkin's lym-
phoma [20].
This case study aims to investigate the extent of dupli-
cation in HTA reports concerning PET for lung cancer
and/or Hodgkin's disease; and to demonstrate the poten-
tial usefulness of a tool for the adaptation of HTA reports,
with a view to conserving resource. In cases where dupli-
cation has occurred, such a toolkit would have been of
great benefit had it been available at the time, facilitating
sharing of information, and saving time.
Methods
Identification of reports
In June 2008 the National Institute for Health Research
(NIHR) CRD HTA database [21] was searched for HTA
reports about the use of PET. The search terms used were
PET or "positron emission tomograph*". There was no
limitation placed on language. Reports published more
than 10 years ago were excluded because of the stage of
development of the technology.
Titles were scanned to identify those reports which
might contain information about the use of PET for lung
cancer and/or Hodgkin's disease. Reports which clearly
related to other areas were listed separately (see Fig 1).
Records were then scanned to establish whether the
reports were written in English, or if versions in English
were available. (English was specified as a criterion as
there was no resource available to translate reports avail-
able only in other languages). The CRD database
included information regarding language of publication
for some reports, for those where this was not clear from
the database, attempts were made to locate the reports on
the internet and establish in which language they were
written. Where reports were written in languages other
than English, these were recorded (see Fig 1).
For the reports where the title suggested they could be
about PET for lung cancer or Hodgkin's disease, written
in English; attempts were made to access full versions of
the reports on the internet. If the reports were not readily
available over the internet or if they were not full reports
but updates of earlier included reports this was also
recorded (see Fig 1).
Finally full reports which were written in English and
freely available over the internet were examined to estab-
lish if they did contain information in relation to the use
of PET in the diagnosis of either lung cancer and/or
Hodgkin's disease (Fig 1).
This study aimed to devise a pragmatic way of assessing
duplication and mimicking what happens in usual prac-
tice. Hence pragmatic decisions were made concerning
the methods for selection of reports (selecting full reports
written in English, available over the internet).Turner et al. Health Research Policy and Systems 2010, 8:16
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Figure 1 Identification of full HTA reports written in English, readily available on the internet, containing information regarding the use of 
PET, in the diagnosis of lung cancer and/or Hodgkin's disease.
Initial search for HTA 
reports about PET in 
CRD HTA db (n=132) 
HTA reports where 
title suggests it 
could be about PET 
for lung cancer or 
Hodgkin’s disease 
(n=56) 
HTA reports where 
title suggested they 
were not about PET 
for lung cancer or 
Hodgkin’s disease 
(n=76) 
Alzheimer’s   6 
Breast cancer    7 
Bone cancer    1 
Cardiology   7 
Cervical/ovarian cancer 
Adnexal mass    3 
Colorectal cancer   5 
Epilepsy    5 
General PET    12 
(technology) 
Gram positive infection  1 
Head/neck/brain/ 
CNS cancer    5 
Huntington’s Disease  1 
Liver cancer    1 
Lymphoma   3 
Melanoma   2 
Neurology   3 
Oesophageal/ 
Laryngeal cancer   5 
Pancreatic cancer   1 
Parkinson’s Disease  1 
Prostate cancer    1 
Soft tissue sarcoma  2 
Stroke    1 
Testicular cancer   1 
Thyroid cancer    2 
 Total   76 
Reports excluded as not 
written in English (n=26): 
Danish   3 
French   4 
German   4 
Norwegian 2 
Portuguese 4 
Spanish   8 
Swedish   1 
Reports excluded because they did not 
contain information about PET in relation to 
lung cancer or Hodgkin’s disease (n=2) 
HTA reports containing 
information about PET for 
lung cancer or Hodgkin’s 
disease, written in English 
and readily available on the 
web (n=16) 
HTA reports excluded because they were 
not full reports i.e. they were brief updates 
of included reports (n=4) 
Full HTA reports containing information about 
PET for lung cancer, written in English and 
readily available on the web (n=12) 
Full HTA reports containing information about PET 
for Hodgkin’s disease, written in English and 
readily available on the web (n=8)
Full HTA reports containing information about PET 
for lung cancer or Hodgkin’s disease, written in 
English and readily available on the web (n=12) 
HTA reports where the 
title suggests they 
could be about PET 
for lung cancer or 
Hodgkin’s disease, 
written in English and 
readily available on 
the web (n=18) 
Reports excluded because 
they could not be readily 
accessed on the web (n=12) 
HTA reports where 
title suggests they 
could be about PET 
for lung cancer or 
Hodgkin’s disease, 
written in English 
(n=30) Turner et al. Health Research Policy and Systems 2010, 8:16
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Examination of reports
The eight reports identified as fulfilling all criteria and
containing information on Hodgkin's disease were then
examined for information regarding:
i) Date of publication and whether they had cited pre-
vious reports identified.
ii) Domains included in the reports. This information
is related to the domains included in the adaptation
toolkit, and was analysed as an indication of the
potential usefulness of the toolkit in these examples.
iii) Purpose of the reports.
Results
Identification of reports
132 records of HTA reports about PET were found in the
initial search of the CRD HTA database. Reading of the
titles enabled 56 records to be selected as potentially con-
taining information about PET in relation to diagnosis of
lung cancer or Hodgkin's disease.
Of these 56, 30 were written in or available in English
and of those, 18 were readily available on the web. Of
those 18, two reports were found not to contain informa-
tion about lung cancer or Hodgkin's disease. Of the
remaining 16 reports four were excluded because they
were not full reports but updates reports already
included.
T h i s  l e f t  1 2  f u l l  r e p o r t s ,  w r i t t e n  i n  E n g l i s h ,  r e a d i l y
available on the web, which contained information con-
cerning the use of PET for the diagnosis of either lung
cancer and/or Hodgkin's disease (see Fig 1). Of these 12
all contained information on lung cancer and 8 also con-
tained information on Hodgkin's disease; these 8 reports
were designated A-H in chronological order of the date of
publication.
Examination of reports
The 8 reports were published between 1999 and 2007
(see Additional file 1, table S1). The second report pub-
lished in 1999 cited the first. All the reports published in
2001 cited the two 1999 reports, but not each other. A
sixth report was published in 2002, citing only 3 of the
earlier 5 reports. The 2005 report cited all from 2001 and
one from 1999. The last report only cited one from 2001,
and the two reports from 2002 and 2005.
All these reports covered four similar domains, tech-
nology use, safety, effectiveness and economic evaluation
(see table 1). Five of the reports also considered organisa-
tional aspects. These five domains are the domains con-
sidered in the adaptation toolkit, and are the sections of
the reports which could therefore lend themselves to the
process of adaptation, facilitated by the toolkit.
The purposes for which the reports were written are
described below:
A [22] 1999. Robert and Milne
This was a three month project which had two objectives:
(i) to review the state of knowledge regarding clinical
applications of PET, and (ii) to determine the key HTA
research questions relating to the use of PET in the UK.
B [23] 1999. Adams et al
INAHTA conducted this joint collaboration in response
to an increasing global interest in the clinical potential of
positron emission tomography (PET). The project docu-
ments PET use and related public health coverage in
countries represented by INAHTA members and synthe-
sizes technology assessments of PET conducted by
INAHTA members and three private US organizations. It
considers all PET systems, that is, conventional full ring
models, newer partial ring models and SPECT cameras
modified for imaging positron emitters.
C [24] 2001. Dussault et al
This assessment report was undertaken following a joint
request from the Fédération des médecins spécialistes du
Québec (FMSQ) and the Conseil québécois de lutte con-
tre le cancer (CQLC) concerning the clinical efficacy of
positron emission tomography (PET). The objectives of
AÉTMIS's assessment were: (a) to gather hard data on the
clinical use of PET in different fields, in particular, oncol-
ogy, neurology and cardiology; and (b) to make recom-
mendations concerning the possible deployment of PET
in Québec.
D [25] May 2001. Laupacis
This health technology assessment of Positron Emission
Tomography (PET) was requested by the Committee on
Technical Fees, a committee consisting of membership
from the Ontario Ministry of Health and Long-Term
Care (MOHL-TC), the Ontario Medical Association
(OMA) and the Ontario Hospital Association (OHA).
The Institute for Clinical Evaluative Sciences (ICES) was
asked to
(a) review the existing literature about the diagnostic
accuracy, effect upon patient outcomes and cost-effec-
tiveness of PET,
(b) identify clinical indications for which PET is likely
to be shown to be diagnostically accurate and cost-effec-
tive in the near future,
(c) estimate the number of patients in Ontario who may
benefit from PET, given current information about its
diagnostic accuracy, effectiveness and cost-effectiveness,
and
(d) identify areas of clinical research related to PET that
are of importance to Ontarians. This report was to con-
sider the clinical use of PET only, not basic research using
PET.
E [26] August 2001. MSAC
The clinical effectiveness of FDG PET had been assessed
previously for 11 indications, in two reviews. This reportTurner et al. Health Research Policy and Systems 2010, 8:16
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summarises the assessment of evidence for FDG PET for
an additional three specific indications: (a) assessment of
patients with lymphoma (Hodgkin's and non-Hodgkin's
lymphoma) for staging of disease prior to therapy; (b)
a s s e s s m e n t  o f  p a t i e n t s  w i t h  s q u a m o u s  c e l l  c a r c i n o m a
(SCC) of the head and neck for staging prior to initial
definitive treatment; and (c) assessment of patients with
sarcoma (soft tissue and bone) for staging and grading of
disease
F [27] 2002. Bradbury et al
This Health Technology Assessment (HTA) set out with
two principal objectives: (a) To determine the role of PET
imaging in cancer management: evaluating the clinical
and cost effectiveness in terms of impact on patient mor-
tality and morbidity. (b) If PET is found to be clinically
and cost effective, to consider the best configuration of
PET facilities (and cyclotrons) to serve the Scottish popu-
lation.
G [28] 2005. Cleemput et al.
The main objectives of this HTA report were to: (a) To
review the existing evidence on the diagnostic accuracy,
clinical effectiveness and cost effectiveness of PET, (b) to
describe the current situation of PET in Belgium, includ-
ing regulation, frequency of use and costs for the national
insurance RIZIV/INAMI, (c) to formulate practical rec-
ommendations for the organisation of PET services in
Belgium based on the existing evidence and data.
H [29] 2007. Facey et al.
The aim of this review was to assess the clinical effective-
ness of FDG-PET in breast, colorectal, head and neck,
lung, lymphoma (Hodgkin's and non-Hodgkin's), mela-
noma, oesophageal and thyroid cancers. For each cancer,
use of FDG-PET to aid management decisions relating to
diagnosis, staging/restaging, recurrence, treatment
response and radiotherapy (RT) planning were evaluated.
All the reports considered the use of PET and develop-
ments, safety, effectiveness and economic evaluation, (see
table 1) although Facey et al 2007 (H) [29] state that the
"study was not intended to evaluate economic reviews of
PET and so did not undertake a search of all economic
sources. However, during the systematic review for effec-
tiveness, some studies of cost effectiveness were identi-
fied". These studies were subsequently verified against
those identified in G [28]. Five of the eight reports con-
sidered organisational aspects.
Discussion
A s  s o  m a n y  o f  t h e  r e p o r t s  c i t e d  p r e v i o u s  r e p o r t s,  t h e
authors must have been aware of the previous work.
Clearly there has been at least some duplication of effort,
in the preparation of these reports. It was stated in D [25]
that while the report was in the process of being written,
the authors became aware that L'Agence d'Évaluation des
Technolgies et des Modes d'Intervention en Santé (AÉT-
Table 1: Date of publication and domains included in reports
Report Year Month Origin Domains
Technology 
use & 
developments
Safety Effectiveness 
(Including 
efficacy)
Economic 
evaluation
Organisational 
aspects
A 1999 July UK yes yes yes yes no
B1 9 9 9 N o v e m b e r I N A H T A  
members
yes yes yes yes no
C 2001 Unknown Québec yes yes yes yes yes
D 2001 May Ontario yes yes yes yes no
E 2001 August Australia yes yes yes yes yes
F 2002 Unknown Scotland yes yes yes yes yes
G 2005 October Belgium yes yes yes yes yes
H 2007 November UK yes yes yes yes yesTurner et al. Health Research Policy and Systems 2010, 8:16
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MIS) in Quebec was also preparing a report on PET scan-
ning [24]. Both groups wrote their reports independently,
but shared drafts of their reports, and met once for a face-
to-face meeting.
Previous work has described the development of a tool-
kit to aid the adaptation of HTA reports [4,10]; from one
setting, for use in another setting: the objectives being to
conserve resource and save time. Some "field testing" of
the toolkit has been undertaken in Europe which has
been found useful, its' testing and development is cur-
rently continuing. The toolkit aims to help the user
decide if new work is required or if existing work can be
adapted for their purposes by prompting questions con-
cerning the quality and relevance of existing reports. This
could be particularly useful for countries with limited
resources as it could enable them to make use of informa-
tion presented by other countries, adapting relevant sec-
tions for their own context. The toolkit provides
checklists and resources for five HTA report domains:
technology use and development, safety, efficacy and
effectiveness, cost-effectiveness and organisational
aspects. All 8 reports considered here, reviewed the first
4 of the 5 domains; 5 reports also considered organisa-
tional aspects.
The four domains considered by all 8 reports contain
the type of information most readily adapted between
contexts [10], (information in the fifth domain, organisa-
tional aspects, is more difficult to adapt to specific coun-
t r i e s  o r  c o n t e x t s ) .  T h i s  c a s e  s t u d y  p r o v i d e s  a  g o o d
example of where a toolkit to aid adaptation would have
been useful had it been available. For example the teams
preparing the two Canadian reports in 2001 (reports C
and D), could have used the toolkit to adapt information
for their own purposes, sharing resource and reducing
the amount of effort required to produce two new
reports; report F published in 2002 cites one of the previ-
ous reports from 2001 (report D), yet did not adapt infor-
mation from the earlier report. It is anticipated that use of
the toolkit in the future will save time, effort and
resource.
Avoiding duplication of HTA reports has been advo-
cated as a means of avoiding duplicating effort unneces-
sarily; however, it should be acknowledged that
sometimes there is a need to produce another HTA
report on the same or a very similar topic. This may
appear to be duplication, but the need is justified. Rea-
sons for this may include i) older HTA reports on a rela-
tively new technology may be very broad in their nature, a
new report may be needed to cover certain aspects in
more detail; ii) rapid evolution of the technology requir-
ing updated evaluation; iii) better methods of assessing
diagnostic tests becoming available; iv) re-analysis of data
using improved statistical methods or v) instructions
from commissioning institution(s) which preclude HTA
teams from building on previous work e.g. NICE.
One strength of this study is the in depth systematic
analysis of the available data. The duplication of HTA
reports is mentioned frequently in the literature; how-
ever, we have not been able to identify any other studies
which have systematically analysed the data to test the
extent to which this is the case for an individual technol-
ogy.
Three possible weaknesses of this study are considered
here. Firstly only reports available in English were
included. Reports written in other languages may have
been relevant, but we lacked resource to be able to trans-
late them, and so the information contained in them was
unfortunately not available to us. Also, only those reports
readily available on the web were considered, paper cop-
ies could have been requested, however, hard copy is not
always readily available.
Searches were restricted to the CRD database; however,
this is the most comprehensive source of completed and
ongoing HTA research from around the world. It is pro-
duced in collaboration with the International Network of
Agencies for Health Technology Assessment (INAHTA)
Secretariat, and contains summaries of ongoing and com-
pleted projects conducted by the INAHTA member
agencies as well as records reporting completed technol-
ogy assessments carried out by other HTA organisations.
Importantly, this database is free to search and so would
be available to less well resourced agencies.
This study only considered one technology, PET, which
is a complex, rapidly evolving diagnostic technology
employed in many disease areas. The results may well
have been different if a less complex technology relevant
to perhaps a single disease area had been considered.
However, use of the toolkit is still relevant, as it prompts
the user to consider and make judgements about issues
such as technology use and development, and as such the
toolkit would still be useful as an aid in considering infor-
mation for possible adaptation. This could be an area for
future research.
Additional material
Conclusions
There was some duplication of effort in the preparation of HTA reports con-
cerned with the use of PET for lung cancer and Hodgkin's disease. This is an 
example of where resource could have been conserved and time saved by the 
use of a toolkit developed to aid in the adaptation of HTA reports from one 
context or country to another.
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